David A. Siegel Ionis Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,092,011 shares of IONS stock, worth $70.1 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,092,011
Previous 1,349,211
55.05%
Holding current value
$70.1 Million
Previous $47.2 Million
33.81%
% of portfolio
0.15%
Previous 0.11%
Shares
31 transactions
Others Institutions Holding IONS
# of Institutions
401Shares Held
146MCall Options Held
916KPut Options Held
552K-
Vanguard Group Inc Valley Forge, PA16.4MShares$549 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.2MShares$542 Million0.32% of portfolio
-
Capital World Investors Los Angeles, CA12.4MShares$414 Million0.06% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$346 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.42MShares$282 Million0.05% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $4.76B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...